<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0"><gtr:id>F4479AD7-66C1-4474-8AB6-E8F33ACCEBC0</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:surname>Baigent</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UU_12026%2F6"><gtr:id>4CFEF3E7-E167-4843-920F-C74D6F5359EB</gtr:id><gtr:title>Meta-analyses of randomized trials studying the effects of treatments on vascular disease risk</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UU_12026/6</gtr:grantReference><gtr:abstractText>For many drugs that influence the risk of major vascular events (heart attacks, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. For several classes of drugs (statins for heart disease and stroke, antiplatelet agents such as aspirin for diabetes, the clot-busting drug alteplase in acute stroke, and angiotensin-receptor blockers in Marfan?s Syndrome) we have established collaborations in which investigators have provided detailed individual patient data from their randomized trials that are addressing a particular clinical question. In each case we aim to generate new combined analyses that provide insights that are not apparent from the individual trials, but which only emerge when the data are combined. These analyses help to identify which patients derive the most benefit (or who are susceptible to harm), and help in developing a better understanding of how each individual treatment works. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.</gtr:abstractText><gtr:technicalSummary>For many drugs that influence the risk of major vascular events (myocardial infarction, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. This programme is focused on several ongoing collaborations in which investigators have provided detailed individual patient data from their randomized trials studying the effects of a particular class of drug. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.
Current work is focused on 4 main areas: 
(i) The Cholesterol Treatment Trialists? (CTT) Collaboration aims to test claims of particular side-effects of statins arising from observational studies (for example, an increased risk of cataract, sleep disturbances, memory loss, or depression), concerns about which are inhibiting prescribing of statins in patients at high risk of cardiovascular disease, with potentially adverse effects on public health. We are currently working with the sponsors of 29 large trials that have previously provided data on vascular events, cancer and mortality in order to obtain supplementary datasets on adverse events, which will then be merged with existing data. We plan to conduct meta-analyses of the effects of statins on a wide range of adverse events once data collection is complete. 
(ii) In accordance with a published protocol, the Stroke Thrombolysis Trialists? (STT) Collaboration has already reported analyses of the effects of alteplase on the proportions surviving without disability and the risks of haemorrhagic stroke in 10 trials conducted in acute ischaemic stroke. We now plan supplementary analyses of the existing database, new data collection to permit analyses of CT scan data, and the incorporation of additional data from completed or ongoing randomized trials. 
(iii) The Antithrombotic Trialists? (ATT) Collaboration is planning updated individual patient data analyses of the effects of aspirin on vascular outcomes in low-risk populations with and without diabetes, which will incorporate the results of major ongoing trials, including the Unit?s own ASCEND trial among 15,000 people with diabetes but no known history of vascular disease.
(iv) The Marfan Trialists? Collaboration (MTC) is preparing to collect individual patient data from 10 randomized trials examining the effects of angiotensin-receptor blockers and of beta-blockers in order to reduce the rate of expansion of the aortic root, which ultimately can lead to fatal aortic rupture.</gtr:technicalSummary><gtr:fund><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2016-07-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>272545</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>63DF0179-0AF9-4068-B761-00C6B3D9AA09</gtr:id><gtr:title>Interpretation of the evidence for the efficacy and safety of statin therapy.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5079851905ee4c5f671c1e3e5a037c87"><gtr:id>5079851905ee4c5f671c1e3e5a037c87</gtr:id><gtr:otherNames>Collins R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b6b5f60ac9d2.54348425</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06D8E6AB-620C-47EF-B012-BFE5725F6CEF</gtr:id><gtr:title>Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.</gtr:title><gtr:parentPublicationTitle>International journal of stroke : official journal of the International Stroke Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00ab49571f031de743ed7cffc95455ea"><gtr:id>00ab49571f031de743ed7cffc95455ea</gtr:id><gtr:otherNames>Hacke W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1747-4930</gtr:issn><gtr:outcomeId>5a7d7ec6a082d1.48023998</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28B8EF6B-7791-4839-9554-5D89040CB0AC</gtr:id><gtr:title>Protocol for analyses of adverse event data from randomized controlled trials of statin therapy.</gtr:title><gtr:parentPublicationTitle>American heart journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de0c7acc1b1b788058c085cccf18b134"><gtr:id>de0c7acc1b1b788058c085cccf18b134</gtr:id><gtr:otherNames>Cholesterol Treatment Trialists' (CTT) Collaboration</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-8703</gtr:issn><gtr:outcomeId>58b6bc458941e1.17232778</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F072332-159D-419F-ABD3-A9F1D82F95E5</gtr:id><gtr:title>Lessons from the controversy over statins - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e076c6ecf685f11a5d56959e53d3dce0"><gtr:id>e076c6ecf685f11a5d56959e53d3dce0</gtr:id><gtr:otherNames>Armitage J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b6b7a8e82f17.35846142</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCB9FCF8-9465-4F62-A9E5-D1E3E809AF9F</gtr:id><gtr:title>Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.</gtr:title><gtr:parentPublicationTitle>Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f467930482c1fdb4e79d78b295a81332"><gtr:id>f467930482c1fdb4e79d78b295a81332</gtr:id><gtr:otherNames>Gross O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0931-0509</gtr:issn><gtr:outcomeId>58b6b5f4d66432.68245880</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8104ECE8-7E03-455A-B1AF-28859B52A59A</gtr:id><gtr:title>Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.</gtr:title><gtr:parentPublicationTitle>Journal of the American College of Cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f3095e5f245a9b4155f07a1154b0c7ea"><gtr:id>f3095e5f245a9b4155f07a1154b0c7ea</gtr:id><gtr:otherNames>Patrono C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0735-1097</gtr:issn><gtr:outcomeId>5a7d7ec62f92e2.11133633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C0CDAD1-BB74-41C6-AD80-3CE4078496BA</gtr:id><gtr:title>Should We Increase GFR with Bardoxolone in Alport Syndrome?</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5a7d7ec6f21346.05384612</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9451C492-5B96-4D93-BFFD-0D85DFA2202F</gtr:id><gtr:title>Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/656eab03d292fe00af58caf39a73fa54"><gtr:id>656eab03d292fe00af58caf39a73fa54</gtr:id><gtr:otherNames>Storey BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5a7d7ec8d2b000.02625888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD451F39-F441-423E-AC89-4D162C80F4E0</gtr:id><gtr:title>Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45e1f44a10cacab8ee373d2181cc2ec7"><gtr:id>45e1f44a10cacab8ee373d2181cc2ec7</gtr:id><gtr:otherNames>Preiss D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5061</gtr:issn><gtr:outcomeId>5a7d7ec72b1c80.76632560</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6F022A4-963A-4CFB-9F53-297F0D4ABA0F</gtr:id><gtr:title>Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.</gtr:title><gtr:parentPublicationTitle>Kidney international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17db3abbe0db607e59b90682b233cf57"><gtr:id>17db3abbe0db607e59b90682b233cf57</gtr:id><gtr:otherNames>Baigent C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0085-2538</gtr:issn><gtr:outcomeId>5a7d7ec6c47e43.94407416</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EB9F057-2184-41E7-B9AD-836CCD7F75B1</gtr:id><gtr:title>Biliary Tract and Liver Complications in Polycystic Kidney Disease.</gtr:title><gtr:parentPublicationTitle>Journal of the American Society of Nephrology : JASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/79df3f08b0a6ddac4f7998cee6e85846"><gtr:id>79df3f08b0a6ddac4f7998cee6e85846</gtr:id><gtr:otherNames>Judge PK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1046-6673</gtr:issn><gtr:outcomeId>5a7d7ec8a26f09.87132850</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C17D9BA4-681F-4C98-B4E0-CFC0BE26A4B9</gtr:id><gtr:title>Are statins useful in patients with advanced chronic kidney disease? - Authors' reply</gtr:title><gtr:parentPublicationTitle>The Lancet Diabetes &amp; Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/079aafb069c9dcc3b9193c395648f372"><gtr:id>079aafb069c9dcc3b9193c395648f372</gtr:id><gtr:otherNames>Herrington W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b6b7a9415e31.38882640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9C6BDD72-0304-498C-ACEE-89423ACA12E4</gtr:id><gtr:title>Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.</gtr:title><gtr:parentPublicationTitle>The lancet. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e2deb820b6a5886cf3ea808012b9fb1"><gtr:id>8e2deb820b6a5886cf3ea808012b9fb1</gtr:id><gtr:otherNames>Scally B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5aa10b6feea440.32864992</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UU_12026/6</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>